|
We asked 50 pharma leaders,  how do you think the reputation of the pharma industry has changed in recent years?
| Improved |
3% |
Stayed the same |
33% |
| Declined |
64% |
 |
|
|
|
|
|
|
|
5 March, 2013
|
| In this Issue |
Countdown Time for the Innovative Medicines Initiative?
Momentum is gathering in Brussels for real battles over carving up the 1 trillion dollars that the EU has now agreed to spend between the end of this year and the end of the decade. The IMI, one of the leading projects benefiting from EU funding is putting everything it can into proving its worth, writes Peter O’ Donnell ...Read more |
EC Authorizes First Therapy for Alcohol Dependence
The European Commission has granted H. Lundbeck A/S marketing authorization for Selincro (nalmefene) for the reduction of alcohol consumption in adult patients with alcohol dependence. The approval applies to all 27 European Union (EU) member states ... Read more |
US: Reflections on Rare Disease Day
The rare disease advocacy community convened last week for its annual Rare Disease Day celebration. Pharm Exec spoke to Peter Saltonstall, CEO of the National Organization for Rare Diseases [NORD] to gauge its assessment of where the movement is heading in an era of growing fiscal pressures on drug spending ... Read more |
Vote for 2013's Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership. And we'd like your input! Tell us who you think should receive Pharmaceutical Executive's Emerging Pharma Leadership Award. Fill out a nomination today ... Read more
|
|
|
|
